Silibinin (an ingredient in Milk Thistle)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | Silibinin (Silymarin) |
| FDA Approval | No |
| Used for | Liver and biliary disorders, adjunct agent in cancer treatment |
| Clinical Trial Phase | Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Few reported; mainly gastrointestinal disturbances |
| OS without | Not specified |
| OS with | Not specified |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | Under investigation; shown to have anti-cancer effects in laboratory studies |
| Usefulness Explanation | Not specified |
| Toxicity Level | Low |
| Toxicity Explanation | Silibinin is considered to have few side effects, with gastrointestinal disturbances being the most common. |
Notes: Silibinin, the active component of Milk Thistle, has shown potential in stabilizing cellular membranes, stimulating detoxification pathways, and inhibiting cancer cell growth in laboratory studies. It has a long history of use for liver and biliary disorders. Clinical trials in cancer are limited but suggest a potential role in enhancing chemotherapy efficacy and reducing toxicity.
Links: * [Milk Thistle (PDQ®)–Health Professional Version - NCI](https://www.cancer.gov/about-cancer/treatment/cam/hp/milk-thistle-pdq)
From Ben Williams Book: Not specified
Loading comments...
